Aug. 21 at 3:00 PM
(NYSE:
$VTAK)
#CatheterPrecision has begun enrollment in the LockeT Compare Study, with the first three patients enrolled. The study will evaluate the safety of the LockeT suture retention device versus internal closure devices, building on data that shows LockeT is safe, effective, and cost-reducing. CEO David Jenkins noted the potential for LockeT to improve patient safety by reducing thrombotic episodes.
https://prismmarketview.com/catheter-precision-begins-enrollment-for-locket-compare-study/